Emergent BioSolutions | EBS - Selling And Administration Expenses


Emergent BioSolutions reported $182.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 187.2M 15.43M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 82.79M 6.13M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Exelixis USD 123.02M 19.9M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.85B 215M Dec/2025
Moderna USD 308M 40M Dec/2025
Myriad Genetics USD 122.3M 6.7M Dec/2025
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pacira USD 91.87M 70K Dec/2025
Pfizer USD 4.08B 894M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
United Therapeutics USD 190.6M 38.6M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Xoma USD 11M 2.54M Jun/2024